pancreatic ductal adenocarcinoma
Conditions
Interventions
Control Group:surgical resection+Gemcitabine+placebo
Study Group:surgical resection+Gemcitabine+AKT cell
Sponsors
Shanghai First Peoples' Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Diagnosed as stage II-III pancreatic ductal adenocarcinoma patients by pathologic histology; 2. Pancreatic cancer after radical resection; 3. Eastern Cooperative Oncology Group Performance Status less than 2; 4. Without radiotherapy or neoadjuvant chemotherapy; 5. The man or the gestation and lactation women Age between 18 to 80 years old; 6. Bone marrow functioned well: ANC more than 1.5*10^9/ L, PLT more than 100*10^9/LHgb more than 9 g/dL; 7. Blood biochemical indicators: AST(SGOT)less than 1.5 ULNALT(SGPT)less than 1.5 ULN, TBIL less than 1.5 ULN; 8. PT and PPT are in normal ranges; 9. Three months prior to clinical research did not receive any other clinical research trials; 10. patients are voluntary, and willing to sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with other malignant tumors in the past five years; 2. Active viral or bacterial infection and cannot be controlled with appropriate anti-infection treatment; 3. Known as HIV infection, active hepatitis B virus or hepatitis C virus infection; 4. Known allergy to any kind of component of study drugs; 5. History of connective tissue disease(Such as lupus, scleroderma, nodular arteritis); 6. Patients with a history of interstitial pneumoniaSlowly progressive difficulty in breathing and hoose Sarcoidosissilicosis Fibrose pulmonaire idiopathiquehylactic pneumonia or A variety of allergy; 7. Suffering from mental illness or other illness, such as heart or lung disease, diabetes, etc. that can not be controlled, and can not cope with study treatment and monitoring requirements; 8. At the same time Patients participate in any other use of interventional medicine clinical research or checkers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival;Safety;Quality of life;Immune index;Biological marker; | — |
Countries
China
Contacts
Public ContactHongxia Wang
Shanghai First Peoples' Hospital
Outcome results
None listed